Autolus Therapeutics (AUTL) Leases (2019 - 2025)
Autolus Therapeutics (AUTL) has disclosed Leases for 7 consecutive years, with $56.6 million as the latest value for Q3 2025.
- For the quarter ending Q3 2025, Leases fell 6.41% year-over-year to $56.6 million, compared with a TTM value of $56.6 million through Sep 2025, down 6.41%, and an annual FY2024 reading of $55.5 million, down 8.71% over the prior year.
- Leases was $56.6 million for Q3 2025 at Autolus Therapeutics, down from $58.6 million in the prior quarter.
- Across five years, Leases topped out at $60.8 million in Q4 2023 and bottomed at $13.2 million in Q3 2022.
- Average Leases over 5 years is $43.3 million, with a median of $55.9 million recorded in 2024.
- The sharpest move saw Leases crashed 63.64% in 2021, then surged 348.83% in 2023.
- Year by year, Leases stood at $18.8 million in 2021, then grew by 23.62% to $23.2 million in 2022, then skyrocketed by 161.92% to $60.8 million in 2023, then dropped by 8.71% to $55.5 million in 2024, then rose by 2.03% to $56.6 million in 2025.
- Business Quant data shows Leases for AUTL at $56.6 million in Q3 2025, $58.6 million in Q2 2025, and $56.2 million in Q1 2025.